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Abstract Paediatric multiple sclerosis (MS) represents
less than 5 % of the MS population, but patients with
paediatric-onset disease reach permanent disability at a
younger age than adult-onset patients. Accurate diagnosis
at presentation and optimal long-term treatment are vital
to mitigate ongoing neuroinflammation and irreversible
neurodegeneration. However, it may be difficult to early
differentiate paediatric MS from acute disseminated en-
cephalomyelitis (ADEM) and neuromyelitis optica spec-
trum disorders (NMOSD), as they often have atypical
presentation that differs from that of adult-onset MS.
The purpose of this review is to summarize the updated
views on diagnostic criteria, imaging, histopathology and
treatment choices.
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Introduction
What is Multiple Sclerosis?
Multiple sclerosis (MS) is an idiopathic inflammatory disorder
characterized by demyelination and degeneration of the cen-
tral nervous system (CNS) [1]. The pathogenesis is complex
and not fully understood [2], but it is an autoimmune disease
with contribution from genetic [3–5] and environmental fac-
tors such as infections, smoking and blood vitamin D levels
[6–8].
MS is a chronic debilitating disease with disease onset typ-
ically in young adulthood, but in a minor proportion of pa-
tients, it starts in childhood. There are many functional do-
mains of living, which can be impaired in a lengthy disease
course, and a substantial proportion of adult MS patients are
economically deprived as a result of unemployment [9].
Clinical Course of Multiple Sclerosis
The heterogeneous clinical course of MS is broadly classified
into three patterns: relapsing-remitting (RRMS), secondary
progressive (SPMS) and primary progressive MS (PPMS).
After the first attack suggestive of MS (clinically isolated syn-
drome (CIS)), more than 85 % of adult-onset patients experi-
ence a relapsing-remitting course; 10 % have a primary pro-
gressive onset with gradual worsening of function [10]. In
contrast to a heterogeneous clinical presentation of clinical
subtypes in adult MS, more than 98 % of paediatric-onset
MS patients have a RRMS course [11–14]. In general, approx-
imately two thirds of RRMS patients eventually evolve within
two decades to SPMS [15•], which is characterized by a pro-
gressive worsening of disability with fewer relapses. The time
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to the transition to SPMS from the first symptom was shown
to be associated with age of onset. Among RRMS patients
whose first symptom was at age 20 years or younger, it was
longer (25.8 years) than those with first symptom at 21 to
30 years (20.2) or at more than 30 years old (15.3) [16].
However, age at conversion to SPMS in patients with
paediatric-onset course was 10 years younger than in those
with adult-onset course (41 vs. 52 years old) [11].
Impact ofMultiple Sclerosis on Patients with Young-Onset
Disease
A paediatric-onset course has been defined in various studies
as having the first acquired CNS inflammatory demyelinating
syndrome at age of less than 16 or 18 years. Some studies also
include those with onset before 20 years. Paediatric-onset MS
represents approximately 2 to 5 % of MS patients [11–13, 17,
18]. The acquired CNS inflammatory demyelinating syn-
dromes comprise optic neuritis, transverse myelitis,
monofocal or multifocal CIS; acute disseminated encephalo-
myelitis (ADEM); or neuromyelitis optica spectrum disorders
(NMOSD). The incidence of acquired CNS inflammatory de-
myelination in the paediatric population is about 0.6 to 1.66
per 100,000 person-years [19–23]. About 32 to 50 % of chil-
dren and adolescents with the first acquired demyelinating
syndrome evolve to MS within 5 years [8, 20, 24–27]. The
impact of MS on those affected young patients is enormous
with multiple adverse medical and psychosocial outcomes.
The common short-term medical problems include seizures,
fatigue, depression, and impairment in mobility, hand func-
tion, and cognition. The proportion of children who need to
repeat the grade in school after the first attack can be as high as
50 % in MS patients, especially those who had their disease
onset after 11 years old [28]. The overall prognosis of
childhood-onset MS tends to be worse than adult-onset MS.
Generally, paediatric patients have a median time of 20 years
to fixed disability and their median age at transition to SPMS
is 10 years younger than in patients with adult-onset disease
[11]. Of those with a disease onset before 20 years of age,
there is a 1.55-fold risk of becoming bedbound from onset
of progression compared to those with onset age larger than
30 years [15•].
The Onset of Puberty Relevant to Paediatric Multiple
Sclerosis
The exact causative factors for paediatric MS are unknown.
There is no significant gender difference in the occurrence of
MS before the age of puberty; however, female sex is a well-
recognized risk factor afterwards [29]. The earlier onset of
menarche was associated with a higher risk of MS in women
in a Canadian population-based study [30]. In addition, for
patients whose onset was at or before menarche, incidence
of relapse was significantly higher during the peri-menarche
period than the post-menarche period [31]. Furthermore, obe-
sity was also associated with an increased risk for MS in
female teenagers but not in boys [32].
Difficulties in Diagnosing Multiple Sclerosis in Paediatric
Populations
The clinical course of early-onset MS differs from that of
adult-onset MS in many ways, and diagnosis is more chal-
lenging. Two diseases mimicking CIS or MS are ADEM
and NMOSD. The differentiation of MS from ADEM and
NMOSD is important for both treatment decision and progno-
sis prediction. Although longitudinally extensive myelitis is a
key diagnostic feature of NMOSD, paediatric patients with
MS and ADEM can also have a spinal cord lesion extending
longer than three continuous vertebral segments. NMOSD can
mimic MS or ADEM since many paediatric patients with
NMOSD have large demarcated cerebral lesions [33, 34].
Up to about 30 % of adults and children with NMOSD have
been reported to have oligoclonal bands (OCBs) in the cere-
brospinal fluid (CSF) [35], which may complicate early clin-
ical distinction of NMOSD from CIS.
Differentiating MS from MS mimics is of treatment and
prognostic importance. Up to 30 % of ADEM patients even-
tually receive a diagnosis of MS after relapses and need a
long-term disease-modifying treatment, while the others have
a monophasic course. Exacerbation of the disease may occur
if a patient with relapsing NMOSD is treated with some
disease-modifying therapies for MS, such as fingolimod
[36], natalizumab [37, 38] or interferon-β [39, 40].
Figure 1 shows the features that distinguish between CIS,
NMOSD, ADEM and MS.
Diagnostic Consensus
An unambiguous early diagnosis is key to effective disease
treatment. The updated diagnostic consensus for CIS, MS,
ADEM and NMOSD led by International Pediatric Multiple
Sclerosis Study Group [41•] is summarized in Table 1. There
is no single clinical or paraclinical method than can ascertain a
diagnosis of the aforementioned inflammatory demyelinating
diseases, and there has to be no better explanation.
CIS, as defined in the adult MS population, refers to optic
neuritis, brain stem syndrome, spinal cord syndrome or an
isolated cerebral hemisphere syndrome [46, 47], and if the
2010 McDonald MRI criteria [45] are fulfilled with evidence
of dissemination in time and in space, the diagnosis of MS can
be made before the second clinical attack [46]. The 2010
McDonald MRI criteria [45] for MS can be applied in those
onset at 12 years of age or older [41•]. The criteria were tested
among patients with incident demyelination aged from 12 and
up to 16 years [48] with a 76 % of positive predictive value
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[48], which is similar to the adult population (79%)[46], while
this value was lower (32 %) in those aged 11 years and
younger [48].
The Role of MRI
Before the advent of magnetic resonance imaging (MRI), the
diagnosis of demyelinating diseases was primarily based on
clinical presentation, physical examination, laboratory tests of
both blood and CSF and electrophysiology. However, many
other diseases, such as brain tumour, maymanifest similarly to
demyelinating lesions and therefore cause diagnostic uncer-
tainty. MRI helps to exclude the other differential diagnoses
without the need to resort to invasive procedures by providing
topographic and pathological information about lesions. In
addition, the evolution of the lesions, which can be clinically
silent, becomes detectable. Furthermore, MRI can be used to
monitor the suspected CNS areas before a lesion forms.
The role of MRI in the management of demyelinating dis-
eases is becoming more and more important. MRI is an essen-
tial modality for the diagnosis of demyelinating diseases. It is
also particularly useful in clinical trials. In addition, this tech-
nique provides a reliable prediction for disease outcome.
Furthermore, there is a trend for increasing integration of
MRI into MS treatment decisions [49].
The 2010 McDonald criteria suggest an MRI scan for the
diagnosis of MS [45], which could also aid early diagnosis of
MS for teenagers aged 12 years and older [48]. After the first
attack (CIS or ADEM), patients having MRI evidence of new
T2 lesions or gadolinium-enhancing lesions separated by a
period of at least 30 days fulfil the MS diagnostic consensus.
However, for those aged younger than 12 years, a minimum of
two clinical events are mandatory to confirm the MS diagno-
sis. The first event can be CIS followed by another ADEM
separated by more than 30 days or ADEM followed by a non-
ADEM event separated by at least 3 months with a MRI dem-
onstrating new lesions [41•]. It is important to note that
NMOSD should be excluded, especially in an Asian popula-
tion, when classifying patients using MRI criteria for MS.
Brain MRI is highly sensitive to white matter lesions. The
MRI in MS (MAGNIMS) consensus recommended mandato-
ry sequences for brain MRI includes (1) axial proton density
and/or T2-fluid-attenuated inversion recovery (FLAIR)/T2-
weighted, (2) sagittal two-dimensional (2D) or 3D T2-
FLAIR and (3) 2D or 3D contrast-enhanced T1-weighted
[50••]. Although axial diffusion-weighted imaging is optional,
it potentially enables differentiation of an acute MS lesion (a
lesion with gadolinium enhancement and increased diffusivi-
ty) from an acute ischaemic lesion (restricted diffusion) [51].
Spinal MRI is not recommended routinely in a patient without
relevant spinal cord symptoms. However, it has value in in-
creasing the sensitivity of MS diagnosis by detecting silent
lesions [52] and also increases the specificity by excluding
mimics [50••].
Contrast agent administration is commonly used to aid the
diagnosis of MS, and it is most sensitive to active lesions
characterized by blood-brain barrier breakdown. Active le-
sions are a common end point of treatment outcomes. There
is some concern regarding patients who receive repeated gad-
olinium in serial MRI in a young population. A recent study
Fig. 1 Key features to differentiate paediatric multiple sclerosis (MS), clinically isolated syndrome (CIS), acute disseminated encephalomyelitis (ADEM)
and neuromyelitis optica spectrum disorders (NMOSD)
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Table 1 Diagnostic consensus for multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM) and neuromyelitis optica spectrum
disorders (NMOSD)
Classification MS [42••] ADEM [41•] NMOSD [43••]
1. CIS
Active
Not active
2. RRMS
Active
Not active
3. SPMS
Active with progression
Active without progression
Not active with progression
Not active without progression
4. PPMS
Active with progression
Active without progression
Not active with progression
Not active without progression (stable disease)
1. Monophasic
2. Multiphasic
1. NMOSD with AQP4
2. NMOSD without AQP4 or
unknown AQP4-IgG Status
CIS:
All are required [41•]
• The first clinical presentation of a
disease that shows characteristics of
inflammatory demyelination that
could be MS but has yet to fulfil
criteria of dissemination in time [44]
• Absence of a prior clinical history of
CNS demyelinating disease (e.g.
absence of past ON, TM,
hemispheric or brain-stem syn-
dromes)
• No encephalopathy that cannot be
explained by fever
• The baseline MRI does not meet the
diagnostic criteria for MS
Definition of active and
progression:
Activity is determined by
• Clinical relapses in the absence of
fever or infarction
And/or
•MRI activity (contrast-enhancing
lesions; new or unequivocally
enlarging T2 lesions assessed at
least annually);
• If assessments are not available,
activity is Bindeterminate^
Progression is measured by clinical
evaluation, assessed at least
annually. If assessments are not
available, activity and
progression are indeterminate.
Monophasic:
All are required [41•]
• A first polyfocal
clinical CNS
event with
presumed
inflammatory
demyelinating
cause
• Encephalopathy
that cannot be
explained by
fever
•No new clinical and
MRI findings
emerge
≥3 months after
the onset
• Brain MRI is
abnormal during
the acute phase
(<3 month)
• Typical brain MRI
findings:
• Diffuse, poorly
demarcated, >1–
2-cm lesions
involving mainly
the cerebral white
matter
• BRare^ T1
hypointense
lesions in the
white matter
• Deep grey matter
lesions can be
present
Multiphasic
Two events
consistent with
ADEM attacks
separated by
≥3 months
NMOSD with AQP4
[43••]
1. At least one core
clinical characteristic
2. Positive test for AQP4-
IgG using best avail-
able detection method
(cell-based assay
strongly recommend-
ed)
3. Exclusion of alternative
diagnoses
NMOSDwithout AQP4 or unknownAQP4-
IgG status [43••]
1. At least two core clinical characteristics
resulting from one or more clinical attacks
and satisfying all of the following
requirements:
(a) At least one of the following: ON, acute
myelitis with LETM or APS
(b) Dissemination in space (>2 different core
characteristics)
(c) MRI requirements, if applicable (see below)
2. Negative test(s) for AQP4-IgG or testing
unavailable
3. Exclusion of alternative diagnoses
RRMS: [41•]
Two clinical events, the first event can be CIS followed by another non-
encephalopathic attack separated by more than 30 days or ADEM
followed by a non-encephalopathic event separated by at least 3 months
with clinical or MRI demonstrated dissemination in space.
Age ≥12 years: 2010 McDonald MRI criteria [45] can be applied
Dissemination in space
Asymptomatic T2 lesion or gadolinium-enhanced lesions in each of two or
more characteristic locations:
• Periventricular
• Juxtacortical
• Infratentorium
• Spinal cord
Dissemination is time
One of the following criteria
(1) New T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irre-
spective of the timing of the baseline scan
(2) Simultaneous presence of asymptomatic gadolinium-enhancing and non-
enhancing lesions at any time
PPMS (very rare in paediatric population): [45]
1 year of disease progression (retrospectively or prospectively determined)
plus 2 of 3 of the following (1) Dissemination is space in the brain
- Presence of one or more T2 lesions in at least one area characteristic of
MS (excluding the spinal cord)
• Periventricular
• Juxtacortical
• Infratentorium
(2) Dissemination in space in the spinal cord - Presence of two or more T2
lesions in the spinal cord
(3) Presence of CSF OCBs and elevated IgG index
Core clinical
characteristics
Most common:
1. Optic neuritis (ON)
2. Acute myelitis (TM)
3. Area postrema
syndrome (APS):
episode of otherwise
unexplained hiccups
or nausea and
vomiting
Less common:
4. Acute brain stem
syndrome
5. Symptomatic narcolepsy
or acute diencephalic
clinical syndrome with
NMOSD-typical dien-
cephalic MRI lesions
6. Symptomatic cerebral
syndrome with
NMOSD-typical brain
lesions
Supporting MRI for NMOSD without AQP4
1. Acute optic neuritis: brain MRI normal or
demonstrating only non-specific white matter
lesions; OR optic nerve MRI with T2-
hyperintense lesion or T1-weighted gadolin-
ium-enhancing lesion extending over >1/2
optic nerve length or involving optic chiasm
2. Acute myelitis: spinal cord MRI showing
attack-associated lesion extending >3 contig-
uous segments (LETM); OR >3 contiguous
segments of focal cord atrophy in patients
with prior history of acute myelitis
3. Area postrema syndrome: dorsal medulla/
area postrema MRI lesion
4. Acute brain stem syndrome: peri-ependymal
brain stem lesions
AQP4 aquaporin-4, APS area postrema syndrome, CIS clinically isolated syndrome, CNS central nervous system, CSF cerebrospinal fluid, IgG
immunoglobulin G, LETM longitudinally extensive transverse myelitis lesions,MSmultiple sclerosis,NMOSD neuromyelitis optica spectrum disorders,
RRMS relapsing-remitting multiple sclerosis,OCBs oligoclonal bands,ON optic neuritis,PPMS primary progressive multiple sclerosis, SPMS secondary
progressive multiple sclerosis, TM transeverse myelitis
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revealed measurable gadolinium amounts in all autopsied
brain samples, with higher concentration in the dentate nucle-
us and globus pallidus in five subjects exposed to two doses of
gadolinium-based contrast agents compared to five unexposed
subjects [53]. None of the examined adult subjects that re-
ceived contrasts had a severely comprised renal function.
The MRI biomarkers to predict MS conversion in paediat-
ric patients with any kind of CNS inflammatory demyelinat-
ing diseases are important. Verhey et al. prospectively ana-
lyzed 332 Canadian paediatric patients aged younger than
16 years old [54]. The presence of at least one Bblack hole^
(a persistent hypointensity for more than 3 months on T1-
wighted imaging) and at least one periventricular lesion
(Dawson’s finger) was found to be sensitive to predict MS
in paediatric patients with any kind of CNS inflammatory
demyelinating diseases [54]. Presence of both parameters
had a higher risk of MS conversion (hazard ratio [HR] 34.2)
than presence of either one or more black holes (HR 20.6) or
one or more Dawson’s fingers (HR 3.3) [54].
Histopathology
A substantial body of literature describes the histopathology
of white matter lesions in MS since the 1980s. Most studies
described both paediatric-onset and adult-onset MS as show-
ing histopathologic heterogeneity [55–59].
Although inflammatory demyelination is practically uni-
versal in the pathology of MS, four pathological patterns have
been described [57]. Briefly, patterns I and II show typical
confluent perivenous demyelinating plaques with T cell-
mediated or T cell plus antibody-mediated processes, respec-
tively. Patterns III and IV show features of oligodendrocyte
dystrophy or extensive loss, respectively, in addition to lym-
phocytic infiltration [57]. These findings not only were nearly
exclusively based on autopsy (more than 82 % lesions) and
biopsy (18% lesions) material from adult MS patients but also
included a very small proportion of paediatric MS patients.
Despite the heterogeneity of lesions between patients, there
seems to be a homogenous pattern in the same patient [57].
Metz et al. examined tissue sampled from different time points
in 22 MS patients, and 21 of them showed the persistence of
the original immunopathological patterns [59].
Comparing white matter lesions sampled for clinical diag-
nosis or autopsy between 19 paediatric and 12 adult MS
[60••], an increased extent of acute axonal damage was noted
in the paediatric group. The extent of acute axonal damage
was positively correlated with a higher Expanded Disability
Status Scale (EDSS; range, 0 to 10; higher scores indicate
more severe disability and 10 indicates death) at the time of
tissue sampling or autopsy. In addition, there were more le-
sions with a diameter more than 2 cm in early active demye-
linating stages and more axonal damage in those with disease
onset before 11 years old [60••].
Cortical lesions inMS have been described in adult patients
but are rare in paediatric patients (66 vs 8 %) [61]. In adults,
the cortical lesions are different fromwhite matter lesions with
a lack of inflammatory cell infiltration. The classification is
based on the location of the lesions: subpial, intracortical and
mixed white matter and grey matter (leukocortical) [62, 63].
Oligoclonal Bands
The presence of intrathecal synthesis of antibodies (OCBs) is
relevant to the diagnosis and prognosis in children with the
first CNS inflammatory demyelinating disease. In a recent
retrospective observational study of 357 children presenting
with isolated optic neuritis, approximately 42 % had OCBs at
disease presentation [64••]. Among these patients, 117/145
(81 %) patients who eventually converted to MS had positive
CSF OCBs at presentation, whereas only 32/212 (15 %) pa-
tients who did not convert to MS had OCBs. In addition, the
presence of OCBs in children might relate to patient age at
onset. Studies showed that there was a higher frequency of
CSF OCBs among paediatric MS with disease onset at
11 years and older (68 %) than those with a younger-onset
age (43 %; odds ratio 2.6 with a 95 % confidence interval 0.8
and 8.8) [65]. Although the presence of OCBs was less fre-
quent in MS patients diagnosed before puberty, after serial
lumbar punctures, many of these patients eventually had pos-
itive OCBs in CSF [60••, 65, 66]. The presence of OCBs in
children with the first CNS inflammatory demyelination is a
predictor for a later relapse and MS diagnosis. However, the
presence OCBs in CSF did not seem to be a good predictor in
Asian paediatric patients [24, 67].
The positive rate of OCBs at the first attack varies in dif-
ferent paediatric population ranging from 44 to 83 % among
those converted to MS [24, 64••, 67–69]. The difference is
probably due to the timing of lumbar puncture in respect to
disease onset, different laboratory techniques and the genetic
background. The large cohort of genetic studies usually in-
cluded paediatric-onset patients for disease course analyses.
A recent large multinational genome-wide association study
(GWAS) in 6950 adult MS patients (multiple countries of UK,
Europe, USA and Australia; age range 2 to 72 years old)
confirmed that genetic factors underlie the positivity of
OCBs in CSF with the major histocompatibility complex
and immunoglobulin heavy chain region being the most im-
portant area of interest. Thus, it appears that the frequency and
diagnostic value of OCBs show no major differences between
the paediatric- and adult-onset MS populations.
Serological Tests
Diagnostic uncertainty often exists in paediatric patients.
For instance, paediatric MS patients can have longitudi-
nally extensive transverse myelitis, which alone does not
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exclude MS [70••]. Serological biomarkers are clinically
useful for differentiating difficult cases and for disease
course prediction. On the one hand, a negative result for
autoantibodies against aquaporin-4 (AQP4) increases the
confidence of MS diagnosis [71, 72]. On the other hand,
testing for autoantibodies against myelin oligodendrocyte
glycoprotein (MOG) potentially facilitates decision-
making for long-term treatment [73, 74].
Autoantibodies to Aquaporin-4
Autoantibodies against AQP4 are specific for NMOSD, and a
positive result of these antibodies in the serum or CSF is
helpful to confirmNMOSD [75]. A growing body of literature
confirmed the high specificity of autoantibodies to AQP4 for
NMOSD diagnosis (85–100 %), although the sensitivity of
various assays is moderate (33–91 %) [71, 72]. However,
unavailability of immunoassays for AQP4 in many clinical
settings hinders its timely usage in urgent clinical practices.
The clinicians should be also aware of the false-positive re-
sults using enzyme-linked immunosorbent assay (ELISA) for
sera and a need for confirmation with live cell-based assay
[72, 76].
Autoantibodies to Myelin Oligodendrocyte Glycoprotein
The presence of serum antibodies to MOG was shown to be
more frequent in patients with a non-MS course, especially in
adults [77, 78]. Approximately a quarter of paediatric patients
with MS and ADEM are positive for anti-MOG antibodies,
which is relatively rare in adult MS [73, 79]. The titres of
autoantibodies to MOG in paediatric MS patients are usually
low and transient if serial serology tests were performed [80].
Less than half of AQP4-seronegative NMOSD patients have
positive serum anti-MOG antibodies [81]. NMOSD patients
with positive anti-MOG antibodies tend to involve younger
adults with a usually monophasic, steroid-dependent clinical
course [43••, 82]. MOG autoantibodies are not disease-
specific since they can also be observed in a proportion of
patients with epilepsy and also in healthy controls [43••].
However, the presence of MOG antibodies in the sera can
potentially guide treatment in patients with demyelinating dis-
ease. For instance, anti-MOG-seropositive optic neuritis has
been noticed to be steroid-sensitive and also steroid-
dependent [83, 84].
Recent research suggests that the presence of antibodies to
MOG in paediatric patients with the first acute CNS inflam-
matory demyelination is less likely to be MS and may need
longer duration of steroid maintenance treatment after pulse
therapy to prevent early relapses. However, there is no stan-
dardized or commercialized assay available and antibodies to
MOG have not been tested in large populations of paediatric
patients.
Cognition in Paediatric Multiple Sclerosis
Most paediatric MS patients experience a recovery of func-
tional deficit, such as problems with gait, vision, bladder and
bowel function, within 12 months from the first attack [70••].
Nevertheless, the cognitive impairment may remain.
Cognitive impairment was shown to affect 31 % of paediatric
patients and the school activities and achievements in 28 %,
within 2 years after disease onset [84]. At 5-year follow-up,
half of patients showed cognitive deterioration, and cognitive
deficit in visual-spatial learning and in expressive language
was observed in 38 % of 48 patients studied [85].
Treatment: Implications and Options
The treatment scheme of paediatric MS includes the acute
management and long-term prevention for relapses.
Although there has been a lack of randomized controlled trials
in paediatric patients, many immunomodulatory and immuno-
suppressive agents have been used [85]. Corticosteroids are
the most commonly used agents for acute disabling relapses;
the most commonly used is intravenous methylprednisolone
(30 mg/kg/day) for 3 to 5 days with or without oral steroid
tapering according to clinical disability persistence. For per-
sistent life-threatening conditions such as respiratory compro-
mise, plasma exchange (5 to 7 cycles in 2 weeks) has been
shown to prevent fatal outcomes and decreased the disability
severity [86]. Alternative managements including intravenous
immunoglobulin G (IVIG) [87] or cyclophosphamide [88]
have been reported.
Immunomodulators are classified into first and second line
with different regulatory approvals between countries, al-
though there is no evidence to support the optimal order
[89]. The first-line disease-modifying therapies (DMTs) for
paediatric MS include interferon (IFN)-1 beta and glatiramer
acetate (GA) [87, 88, 90, 91]. Whereas IFN was more com-
monly prescribed than GA, both agents result in a 24–40 %
reduction in disability progression in paediatric and adult
RRMS and their long-term side effects were similar between
paediatric and adult MS [87]. The clinical efficacy is not dif-
ferent between IFN and GA, but IFN reduces the MRI lesion
burden more than GA [92].
The long-term safety of the first-line DMTs is good, as no
secondary malignancy or progressive mult i focal
leukoencephalopathy (PML) has been reported in paediatric
or adult users. The adverse effects to interferon-beta 1b in
paediatric MS patients were similar to adults, with flu-like
symptoms in one third of patients, abnormal liver function
profile in one fourth and injection site reaction in one fifth
[87, 91]. Similar adverse events were reported in about 30 %
of GA paediatric users [87]. However, poor tolerability of
first-line DMTs was reported to occur in about one in eight
paediatric users [90]. Approximately 30 % of all paediatric
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patients treated with first-line DMTs were non-responders,
with more than one clinical relapse per year or MRI changes
while on therapy [90].
It is usually reasonable to switch to a second-line DMT
when there is breakthrough disease activity, such as disease
relapse or new MRI T2 lesions. The common choices for
paediatric patients include intravenous natalizumab and oral
fingolimod.
Natalizumab
Natalizumab is a humanized recombinant monoclonal an-
tibody against the α4-integrin, which diminishes leuko-
cyte migration across the blood-brain barrier from the pe-
ripheral blood into the CNS [93]. Natalizumab was shown
to reduce annual relapse rate by 68 %, reduced cerebral
MRI disease activity and sustained EDSS progression at
2 years among adult RRMS patients [94, 95]. It has also
been shown to be potentially effective in paediatric pa-
tients. Kornek et al. reported 20 paediatric RRMS patients
who had reduced annual relapse rates and new T2 lesions
after natalizumab administration [96]. However, they also
found relapse activity within 6 months in six of eight
patients after discontinuation of natalizumab therapy
[96]. Ghezzi et al. also confirmed the efficacy in regis-
tered Italian paediatric patients receiving natalizumab and
showed that no evidence of disease activity (NEDA) oc-
curred in 58 % of cases compared to the pre-treatment
status [97] and side effects were mild and tolerable [98].
The risk of progressive multifocal leukoencephalopathy
(PML) has been studied in adult RRMS patients, and the risk
factors include prolonged use of natalizumab (>2 years), prior
immunosuppressive treatment and the presence of antibodies to
the John Cunningham virus (JCV) [99, 100]. The seropreva-
lence of JCV in German children and adolescents with MS or
other neurological conditions was shown to be around 30 %,
which was about half of the seropositivity in adults [101, 102].
A higher anti-JCV antibody titre may predict higher risk of
PML [99], and therefore, serial follow-up of viral titres or
watching for seroconversion from seronegative subjects can
preclude the high-risk patients. In addition, Huppke et al. stud-
ied the prevalence of anti-JCVantibodies in German paediatric
MS patients and found at least twice as high as that reported in
studies of non-MS children [103]. The risk of malignancy is not
very high among adult natalizumab users (about <0.1 %, 7/24
cases with malignancies were breast cancer) [104] whereas
careful surveillance is warranted in paediatric users who were
in transition to young adulthood.
Fingolimod
Fingolimod is the first approved oral DMT for MS patients,
which has been shown to be moderately effective [105]. Its
mechanism is to prevent the egress of lymphocytes from
lymph nodes via binding to the receptor for sphingosine-1-
phosphate (S1P) on lymphocytes [106]. The short-term side
effects in 17 Brazilian paediatric RRMS patients were similar
to those in adult patients: asymptomatic bradycardia, genital
herpes and isolated infection of the upper respiratory tract or
urinary tract [107, 108]. Although the long-term experience in
paediatric MS is still limited, rebound inflammatory effects on
cerebral lesions in a 19-year-old childhood-onset patient indi-
cate the need of a cautious withdrawal at a slower pace, if
discontinuation of fingolimod is necessary [109].
Newer Oral Disease-Modifying Therapies
Teriflunomide was the second oral disease-modifying
agent approved for adult MS [110]. Its primary mecha-
nism is hypothesized to relate to inhibition of the prolif-
eration of stimulated T or B lymphocytes [111]. Dimethyl
fumarate (DMF, also called BG-12) is the latest oral
disease-modifying agent in adults since 2013 [112]. The
mechanism by which DMF exerts its therapeutic effect in
MS is unknown, but it may affect the metabolism and
signalling of immune cells. The safety and efficacy of
these two agents have not yet been evaluated in paediatric
MS patients.
Conclusions
The formal diagnosis of MS should always take into consid-
eration the clinical, imaging and serology or, if necessary,
histopathology findings. In addition, no better explanation
for the neurological syndrome should be present. When there
is diagnostic uncertainty, serum antibodies against aquaporin-
4 or MOG may be helpful in diagnosis (by ruling out the
alternative diagnosis of NMOSD) and treatment. Optimal
long-term DMT treatment in paediatric MS has not been well
established, but there is experience of first-line treatment with
IFN and GA and these are safe. There is also emerging expe-
rience with second-line DMT such as natalizumab and
fingolimod; however, close monitoring for severe adverse
events including PML and malignancy is warranted.
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